VALN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Valneva SE (VALN) is not a strong buy for a beginner, long-term investor at this time. The stock exhibits bearish technical indicators, lacks positive trading signals, and has no recent news or significant catalysts to support immediate growth. While analysts see potential in the company's Lyme disease vaccine, the stock's current weakness and lack of momentum suggest holding off for now.
The MACD is below zero and negatively contracting, indicating bearish momentum. The RSI is neutral at 29.32, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 5.886, with resistance at 6.556. The stock is currently trading near its pivot point of 6.221, showing limited immediate upside potential.
Jefferies reiterated a Buy rating with a $15 price target, citing potential approval for the Lyme disease vaccine despite a statistical miss in Phase 3 results. Analysts believe the stock's weakness presents a buying opportunity.
Technical indicators are bearish, and there is no recent news or significant trading trends from hedge funds or insiders. The stock has a 70% chance of declining 3.9% over the next month based on historical patterns.
No financial data available for assessment.
Jefferies reiterated a Buy rating with a $15 price target, suggesting long-term potential despite short-term weakness.
